Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Jetstar to Charge for Overhead Cabin Bags From February 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Apple Restores Telegram to App Store After Content Policy Violation 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
AUSTIN, Texas, March 19, 2018 -- Molecular Templates, Inc., (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in oncology, today announced that its management will provide a corporate overview at the Oppenheimer 28th Annual Healthcare Conference, taking place March 20-21 at the Westin New York Grand Central hotel in New York City.
| Presentation Details | ||
| Date: | Wednesday, March 21 | |
| Time: | 10:20am Eastern Time | |
| Location: | Track 3 | |
About Molecular Templates
Molecular Templates is focused on the discovery, development and commercialization of next-generation immunotoxins called Engineered Toxin Bodies (ETBs) for the treatment of cancers and other serious diseases. For additional information, please visit Molecular Templates’ website at www.mtem.com.
Investor Contact:
Andrew McDonald, Ph.D.
[email protected]
646-597-6987
Adam Cutler
Chief Financial Officer
[email protected]
862-204-4006
